ARDT — ARDENT HEALTH INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About ARDENT HEALTH INC (ARDT)
ARDENT HEALTH INC (ARDT) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $7M. Across recent filings, tracked investors recorded 5 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in ARDT
How many top investors track ARDT
A small number of top investors own this.
ARDT Ownership Composition
How ARDENT HEALTH INC is held across tracked investor types, based on reported 13F positions.
- Other94.5%
- Hedge Funds5.5%
Tracked investors reporting ARDT
- Izzy EnglanderMar 31, 2026Millennium ManagementShares66.3KValue$567.9K% Portfolio0.00%
- Ken GriffinMar 31, 2026Citadel AdvisorsShares168.9KValue$1.4M% Portfolio0.00%
- Steve CohenDec 31, 2025Point72 Asset ManagementShares13.2KValue$116.2K% Portfolio0.00%
Recent activity
- $7.5MFeb 17, 2026
- $567.9KMay 15, 2026
- New$116.2KFeb 17, 2026
- New$1.4MMay 15, 2026
- New$225.3KNov 14, 2025
Frequently asked questions
- How many institutional investors hold ARDT?
- 3 tracked institutional investors disclosed a position in ARDT (ARDENT HEALTH INC) in their most recent 13F filing.
- Who is the largest institutional holder of ARDT?
- Izzy Englander, Millennium Management, holds the largest disclosed position in ARDT, valued at $7M.
- Did institutional ownership of ARDT increase or decrease?
- Across recent 13F filings, tracked investors recorded 5 new positions, 0 increased, 0 reduced, and 0 fully exited ARDT.
- Where does this ARDT ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.